La Jolla, California--(Newsfile Corp. - January 13, 2021) - Tryp Therapeutics, a leading pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today it has been invited to present at two upcoming industry conferences in January and February 2021.
La Jolla, California--(Newsfile Corp. - January 13, 2021) - Tryp Therapeutics, a leading pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today it has been invited to present at two upcoming industry conferences in January and February 2021.
Edison Group:
Global Healthcare Conference 2021
Date: January 26-28th, 2021
https://www.edisongroup.com/event/open-house-global-healthcare-2021/
Canaccord Genuity:
Psychedelics Conference: New Paradigms & Treatment Approaches in Health.
Date: February 3-4, 2021
“We are extremely excited and honored to be invited to speak and present at both the Edison Global Healthcare Conference and Canaccord’s Psychedelic Conference later this month”, said Jim Kuo, CEO at TRYP Therapeutics. “As we move our development pipeline forward into the clinic, continuing to share our story, expand our investor base and connecting with new networks of potential shareholders is critical to the growth of our company”.
Information on each event, as well as links to presentations as they become available closer to the event, will be posted on Tryp’s event page, which can be found at: https://www.tryptherapeutics.com/investors/events
About Tryp Therapeutics:
Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and/or safety profiles for the treatment of rare diseases and other diseases with high unmet medical needs. Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN™, program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain neuropsychiatric-based disorders.
Tryp’s lead PFN™ drug candidate is TRP-8802 for the treatment of fibromyalgia, a chronic pain syndrome estimated to affect more than 5 million people in the United States.
In addition to its PFN™ Program, Tryp is developing TRP-1001, an oral formulation of razoxane for the treatment of soft tissue sarcoma. Soft tissue sarcomas are a rare and diverse group of tumors that account for about 1% of all cancers in adults and 7% in children. Based on the prevalence of soft tissue sarcomas in the United States, Tryp believes it is a rare disease and that TRP-1001 should qualify for Orphan Drug status.
Contact:
For inquiries, please contact us at:
TRYP Investor Relations
T: 1-833-811-TRYP (8797)
E: investors@tryptherapeutics.com
Forward-Looking Information
Certain information in this news release, including statements relating to the anticipated date that the Common Shares will commence trading on the Canadian Securities Exchange constitutes forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events.
Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the “Risk Factors” section of the Prospectus available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/71913
